Evidence map›Paper›PMID 29355304›Full record

ArticleChemical research in toxicology2018

Computationally Assessing the Bioactivation of Drugs by N-Dealkylation.

Na Le Dang, Tyler B Hughes, Grover P Miller, S Joshua Swamidass

Abstract read
In one paragraph

Article in Chemical research in toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 66 citations in OpenAlex.

  1. In silico analysis ofIn silico pharmacology · 2026
    Article
  2. Evaluation of the Activity of Amino Chalcone AgainstPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Bioactive structures for inhibitors ofFuture medicinal chemistry · 2025
    Article
  8. Chemical Composition and Larvicidal Activity AgainstMolecules (Basel, Switzerland) · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Mild and Functional Group-Tolerant AerobicThe Journal of organic chemistry · 2023
    Article
  13. Message Passing Neural Networks Improve Prediction of Metabolite Authenticity.Journal of chemical information and modeling · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.Journal of chemical information and modeling · 2020
    Article
  19. Article
  20. XenoNet: Inference and Likelihood of Intermediate Metabolite Formation.Journal of chemical information and modeling · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Na Le DangDepartment of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States.
Tyler B HughesDepartment of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States.ORCID 0000-0001-6221-9014
Grover P MillerDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences , Little Rock, Arkansas 72205, United States.
S Joshua SwamidassDepartment of Pathology and Immunology, Washington University School of Medicine , Campus Box 8118, 660 S. Euclid Ave., St. Louis, Missouri 63110, United States.ORCID 0000-0003-2191-0778
Washington University in St. Louis · USUniversity of Arkansas for Medical Sciences · US

Funding

NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
HIGH PERFORMANCE BIOMEDICAL IMAGING COMPUTER RESOURCESS10RR022984 · NCRR · WASHINGTON UNIVERSITY · PI PRIOR, FRED WILLIAM · 2009 to 2009
$1.9M
DATA AND TOOLS FOR MODELING METABOLISM AND REACTIVITYR01LM012222 · NLM · WASHINGTON UNIVERSITY · PI MILLER, GROVER P, SWAMIDASS, SANJAY JOSHUA · 2016 to 2019
$1.5M
Computationally modeling the impact of ontogeny on drug metabolic fateR01LM012482 · NLM · UNIV OF ARKANSAS FOR MED SCIS · PI MILLER, GROVER P, SWAMIDASS, SANJAY JOSHUA · 2016 to 2019
$1.3M
GPU COMPUTING RESOURCE TO ENABLE INNOVATION IN IMAGING AND NETWORK BIOLOGYS10OD018091 · OD · WASHINGTON UNIVERSITY · PI PAPPU, ROHIT V, PRIOR, FRED WILLIAM · 2014 to 2014
$598k
NCRR NIH HHS S10 RR022984NIGMS NIH HHS T32 GM007200NIH HHS S10 OD018091NLM NIH HHS R01 LM012222NLM NIH HHS R01 LM012482
6 · The paper itself

Abstract

Cytochromes P450 (CYPs) oxidize alkylated amines commonly found in drugs and other biologically active molecules, cleaving them into an amine and an aldehyde. Metabolic studies usually neglect to report or investigate aldehydes, even though they can be toxic. It is assumed that they are efficiently detoxified into carboxylic acids and alcohols. Nevertheless, some aldehydes are reactive and escape detoxification pathways to cause adverse events by forming DNA and protein adducts. Herein, we modeled N-dealkylations that produce both amine and aldehyde metabolites and then predicted the reactivity of the aldehyde. This model used a deep learning approach previously developed by our group to predict other types of drug metabolism. In this study, we trained the model to predict N-dealkylation by human liver microsomes (HLM), finding that including isozyme-specific metabolism data alongside HLM data significantly improved results. The final HLM model accurately predicted the site of N-dealkylation within metabolized substrates (97% top-two and 94% area under the ROC curve). Next, we combined the metabolism, metabolite structure prediction, and previously published reactivity models into a bioactivation model. This combined model predicted the structure of the most likely reactive metabolite of a small validation set of drug-like molecules known to be bioactivated by N-dealkylation. Applying this model to approved and withdrawn medicines, we found that aldehyde metabolites produced from N-dealkylation may explain the hepatotoxicity of several drugs: indinavir, piperacillin, verapamil, and ziprasidone. Our results suggest that N-dealkylation may be an under-appreciated bioactivation pathway, especially in clinical contexts where aldehyde detoxification pathways are inhibited. Moreover, this is the first report of a bioactivation model constructed by combining a metabolism and reactivity model. These results raise hope that more comprehensive models of bioactivation are possible. The model developed in this study is available at http://swami.wustl.edu/xenosite/ .

Indexed as

AldehydesAminesDealkylationHumansIndinavirLiverMicrosomes, LiverModels, MolecularMolecular StructurePiperacillinPiperazinesThiazolesVerapamilAldehydesAminesIndinavirPiperacillinPiperazinesThiazolesVerapamilziprasidone

Identifiers

PMID29355304
PMCPMC5871345
OpenAlexW2784645165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.